Cargando…
Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom
BACKGROUND: Mutations in the CDKN2A and CDK4 genes predispose to melanoma. From three case-control studies of cutaneous melanoma, we estimated the prevalence and predictors of these mutations for people from regions with widely differing latitudes and melanoma incidence. METHODS: Population-based ca...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361137/ https://www.ncbi.nlm.nih.gov/pubmed/25780468 http://dx.doi.org/10.1186/1897-4287-12-20 |
_version_ | 1782361609295888384 |
---|---|
author | Harland, Mark Cust, Anne E Badenas, Celia Chang, Yu-Mei Holland, Elizabeth A Aguilera, Paula Aitken, Joanne F Armstrong, Bruce K Barrett, Jennifer H Carrera, Cristina Chan, May Gascoyne, Joanne Giles, Graham G Agha-Hamilton, Chantelle Hopper, John L Jenkins, Mark A Kanetsky, Peter A Kefford, Richard F Kolm, Isabel Lowery, Johanna Malvehy, Josep Ogbah, Zighereda Puig-Butille, Joan-Anton Orihuela-Segalés, Jordi Randerson-Moor, Juliette A Schmid, Helen Taylor, Claire F Whitaker, Linda Bishop, D Timothy Mann, Graham J Newton-Bishop, Julia A Puig, Susana |
author_facet | Harland, Mark Cust, Anne E Badenas, Celia Chang, Yu-Mei Holland, Elizabeth A Aguilera, Paula Aitken, Joanne F Armstrong, Bruce K Barrett, Jennifer H Carrera, Cristina Chan, May Gascoyne, Joanne Giles, Graham G Agha-Hamilton, Chantelle Hopper, John L Jenkins, Mark A Kanetsky, Peter A Kefford, Richard F Kolm, Isabel Lowery, Johanna Malvehy, Josep Ogbah, Zighereda Puig-Butille, Joan-Anton Orihuela-Segalés, Jordi Randerson-Moor, Juliette A Schmid, Helen Taylor, Claire F Whitaker, Linda Bishop, D Timothy Mann, Graham J Newton-Bishop, Julia A Puig, Susana |
author_sort | Harland, Mark |
collection | PubMed |
description | BACKGROUND: Mutations in the CDKN2A and CDK4 genes predispose to melanoma. From three case-control studies of cutaneous melanoma, we estimated the prevalence and predictors of these mutations for people from regions with widely differing latitudes and melanoma incidence. METHODS: Population-based cases and controls from the United Kingdom (1586 cases, 499 controls) and Australia (596 early-onset cases, 476 controls), and a hospital-based series from Spain (747 cases, 109 controls), were screened for variants in all exons of CDKN2A and the p16INK4A binding domain of CDK4. RESULTS: The prevalence of mutations for people with melanoma was similar across regions: 2.3%, 2.5% and 2.0% for Australia, Spain and the United Kingdom respectively. The strongest predictors of carrying a mutation were having multiple primaries (odds ratio (OR) = 5.4, 95% confidence interval (CI: 2.5, 11.6) for 2 primaries and OR = 32.4 (95% CI: 14.7, 71.2) for 3 or more compared with 1 primary only); and family history (OR = 3.8; 95% CI:1.89, 7.5) for 1 affected first- or second-degree relative and OR = 23.2 (95% CI: 11.3, 47.6) for 2 or more compared with no affected relatives). Only 1.1% of melanoma cases with neither a family history nor multiple primaries had mutations. CONCLUSIONS: There is a low probability (<2%) of detecting a germline CDKN2A mutation in people with melanoma except for those with a strong family history of melanoma (≥2 affected relatives, 25%), three or more primary melanomas (29%), or more than one primary melanoma who also have other affected relatives (27%). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1897-4287-12-20) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4361137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43611372015-03-17 Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom Harland, Mark Cust, Anne E Badenas, Celia Chang, Yu-Mei Holland, Elizabeth A Aguilera, Paula Aitken, Joanne F Armstrong, Bruce K Barrett, Jennifer H Carrera, Cristina Chan, May Gascoyne, Joanne Giles, Graham G Agha-Hamilton, Chantelle Hopper, John L Jenkins, Mark A Kanetsky, Peter A Kefford, Richard F Kolm, Isabel Lowery, Johanna Malvehy, Josep Ogbah, Zighereda Puig-Butille, Joan-Anton Orihuela-Segalés, Jordi Randerson-Moor, Juliette A Schmid, Helen Taylor, Claire F Whitaker, Linda Bishop, D Timothy Mann, Graham J Newton-Bishop, Julia A Puig, Susana Hered Cancer Clin Pract Research BACKGROUND: Mutations in the CDKN2A and CDK4 genes predispose to melanoma. From three case-control studies of cutaneous melanoma, we estimated the prevalence and predictors of these mutations for people from regions with widely differing latitudes and melanoma incidence. METHODS: Population-based cases and controls from the United Kingdom (1586 cases, 499 controls) and Australia (596 early-onset cases, 476 controls), and a hospital-based series from Spain (747 cases, 109 controls), were screened for variants in all exons of CDKN2A and the p16INK4A binding domain of CDK4. RESULTS: The prevalence of mutations for people with melanoma was similar across regions: 2.3%, 2.5% and 2.0% for Australia, Spain and the United Kingdom respectively. The strongest predictors of carrying a mutation were having multiple primaries (odds ratio (OR) = 5.4, 95% confidence interval (CI: 2.5, 11.6) for 2 primaries and OR = 32.4 (95% CI: 14.7, 71.2) for 3 or more compared with 1 primary only); and family history (OR = 3.8; 95% CI:1.89, 7.5) for 1 affected first- or second-degree relative and OR = 23.2 (95% CI: 11.3, 47.6) for 2 or more compared with no affected relatives). Only 1.1% of melanoma cases with neither a family history nor multiple primaries had mutations. CONCLUSIONS: There is a low probability (<2%) of detecting a germline CDKN2A mutation in people with melanoma except for those with a strong family history of melanoma (≥2 affected relatives, 25%), three or more primary melanomas (29%), or more than one primary melanoma who also have other affected relatives (27%). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1897-4287-12-20) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-20 /pmc/articles/PMC4361137/ /pubmed/25780468 http://dx.doi.org/10.1186/1897-4287-12-20 Text en © Harland et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Harland, Mark Cust, Anne E Badenas, Celia Chang, Yu-Mei Holland, Elizabeth A Aguilera, Paula Aitken, Joanne F Armstrong, Bruce K Barrett, Jennifer H Carrera, Cristina Chan, May Gascoyne, Joanne Giles, Graham G Agha-Hamilton, Chantelle Hopper, John L Jenkins, Mark A Kanetsky, Peter A Kefford, Richard F Kolm, Isabel Lowery, Johanna Malvehy, Josep Ogbah, Zighereda Puig-Butille, Joan-Anton Orihuela-Segalés, Jordi Randerson-Moor, Juliette A Schmid, Helen Taylor, Claire F Whitaker, Linda Bishop, D Timothy Mann, Graham J Newton-Bishop, Julia A Puig, Susana Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom |
title | Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom |
title_full | Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom |
title_fullStr | Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom |
title_full_unstemmed | Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom |
title_short | Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom |
title_sort | prevalence and predictors of germline cdkn2a mutations for melanoma cases from australia, spain and the united kingdom |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361137/ https://www.ncbi.nlm.nih.gov/pubmed/25780468 http://dx.doi.org/10.1186/1897-4287-12-20 |
work_keys_str_mv | AT harlandmark prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT custannee prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT badenascelia prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT changyumei prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT hollandelizabetha prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT aguilerapaula prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT aitkenjoannef prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT armstrongbrucek prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT barrettjenniferh prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT carreracristina prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT chanmay prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT gascoynejoanne prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT gilesgrahamg prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT aghahamiltonchantelle prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT hopperjohnl prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT jenkinsmarka prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT kanetskypetera prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT keffordrichardf prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT kolmisabel prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT loweryjohanna prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT malvehyjosep prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT ogbahzighereda prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT puigbutillejoananton prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT orihuelasegalesjordi prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT randersonmoorjuliettea prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT schmidhelen prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT taylorclairef prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT whitakerlinda prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT bishopdtimothy prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT manngrahamj prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT newtonbishopjuliaa prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom AT puigsusana prevalenceandpredictorsofgermlinecdkn2amutationsformelanomacasesfromaustraliaspainandtheunitedkingdom |